Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29092709 | 0.88 | KDM4E (0.78) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL28998878 | 0.88 | KDM4E (0.78) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL29415000 | 0.86 | KDM4E (0.84) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL28137387 | 0.86 | KDM4E (0.84) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| 2,3-Dihydroxy-4-Methoxy-4'-Ethoxybenzophenone SCHEMBL4007549 | 0.84 | MAPT (1.00) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL29415019 | 0.83 | KDM4E (0.70) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL2488063 | 0.83 | KDM4E (0.70) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| 3,4-Didesmethyl-5-Deshydroxy-3'-Ethoxyscleroin SCHEMBL12998336 | 0.82 | HPGD (1.00) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL93601 | 0.82 | MAPT (0.69) | KDM4EMAPTALDH1A1HPGDALOX15 | |
| SCHEMBL18127697 | 0.82 | ALDH1A1 (0.69) | KDM4EMAPTALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | claimed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| US-20110189310-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2011-08-04 | — | — | US | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
| US-10233422-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20170114324-A1 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | TYLER MEDICAL RESEARCH, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2010042728-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009081141-A1 | BENZOPHENONE COMPOUNDS | UNIVERSITY OF SHEFFIELD (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009081141-A1 | BENZOPHENONE COMPOUNDS | UNIVERSITY OF SHEFFIELD (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009003147-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PARKINSON'S INSTITUTE (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | KDM4E 4389/4885MAPT 55/4885ALDH1A1 2223/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | KDM4E 4335/4885MAPT 69/4885ALDH1A1 2054/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | KDM4E 3739/4885MAPT 357/4885ALDH1A1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.